Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study to Assess the Virologic Efficacy of REGN10933+REGN10987 Across Different Dose Regimens in Outpatients With SARS-CoV-2 Infection

NCT04666441 is registered in ClinicalTrials.gov with Regeneron Pharmaceuticals as lead sponsor.

NCT NCT04666441
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04666441 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study to Assess the Virologic Efficacy of REGN10933+REGN10987 Across Different Dose Regimens in Outpatients With SARS-CoV-2 Infection
Lead sponsor
Regeneron Pharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
December 15, 2020
Completion date
September 21, 2021
Enrollment
1,149 (actual)
Sites
57

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19